This Project Grant award of $400,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop inhaled xenon gas (Xe) as a novel treatment for opioid withdrawal syndrome (OWS). The research, conducted by General Biophysics LLC in partnership with McLean Hospital and Brigham & Women's Hospital, seeks to demonstrate Xe's ability to attenuate OWS by inhibiting sympathetic nervous system activity and inflammation....
The National Institute on Drug Abuse (NIDA) awarded a $318,875 project grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Spark Biomedical Inc., a medical equipment manufacturer, to develop a machine learning algorithm that can detect opioid withdrawal symptoms and cravings. The goal is to integrate this algorithm with Spark Biomedical's Sparrow Ascent transcutaneous auricular neurostimulation (TAN) system to create a closed-loop system that can monitor patients and deliver...
This $479,731 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support the development of NARCOBOND A2/MO, a "nanosponge" containing decoy receptors for the opioid fentanyl and the veterinary sedative xylazine. The goal is to create a treatment that can safely sequester both substances in the peripheral blood, preventing their entry into the central nervous system and reversing life-threatening...
This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $640,000 to Olfa Thera, Inc. to develop new therapeutics targeting the OLFR78/OR51E2 receptor pathway in the carotid body. The goal is to identify OLFR78/OR51E2 agonists that can strongly stimulate carotid body activity and ventilation to reverse opioid-induced respiratory depression, without the side effects of existing...
This $340,000 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research at the Washington University in St. Louis to investigate the role of excitatory glutamatergic inputs from the ventral tegmental area (VTA) to the locus coeruleus-noradrenergic (LC-NE) system in fentanyl withdrawal-induced negative affective behaviors. The overall goal is to better understand the contribution of the LC-NE system...
The National Institute on Drug Abuse (NIDA) awarded a $497,733 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Washington University in St. Louis to conduct research on the central amygdala's role in oxycodone withdrawal. The central hypothesis is that activation of specific neuronal subpopulations within the central amygdala is necessary and sufficient for expressing somatic opioid withdrawal symptoms and contributing to future drug-seeking behaviors....
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under CFDA Program 93.279 "Drug Use and Addiction Research Programs", provides $277,389 to Synventa LLC to conduct preclinical proof-of-concept studies on the ability of the respiratory stimulant drug Etimizol to reverse respiratory depression induced by the opioid-xylazine drug combination.
The key objectives are to (1) characterize the respiratory depression effects of xylazine alone and in...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $404,917 Project Grant to Quench Medical Inc. to develop and test an inhaled dry powder formulation containing the psychoplastogenic compound 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for treating opioid use disorder (OUD). The project aims to create a targeted inhalation treatment that can effectively and consistently deliver 5-MeO-DMT to the lungs and systemic...
This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $799,978 in funding to Predictably Human, Inc. to support the continued development of "NOMORE", a digitally controlled aerosolized nicotine replacement therapy.
The key objectives of this STTR Fast-Track program are to complete the prototype development, conduct proof-of-concept testing, prepare and submit a pre-IND package, and initiate GLP...
The National Institute on Drug Abuse (NIDA) awarded a $2,925,374 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Clear Scientific, LLC to develop a novel reversal agent for treating overdoses from the combination of fentanyl and xylazine. The funding will support a 2-year research project with the goal of identifying a lead candidate compound that can simultaneously restore respiration and reverse sedation caused by these co-ingested substances. Key...
Nobilis Therapeutics Inc. received a $959,976 Project Grant award from the National Institute on Drug Abuse within the Department of Health and Human Services' National Institutes of Health to develop a portable hand-held xenon inhaler device for rapidly reducing opioid withdrawal symptoms. The award, made on September 30, 2021 under the Drug Abuse and Addiction Research Programs (CFDA 93.279) federal grant program, will fund preclinical proof-of-concept studies through May 29, 2023 to evaluate whether inhaled xenon gas can attenuate withdrawal severity in morphine-dependent mice. If proven effective, Nobilis Therapeutics plans to file an investigational new drug application for a subsequent $959k human clinical trial to assess whether xenon decreases withdrawal symptoms during medically-managed opioid tapering required before buprenorphine initiation for opioid use disorder treatment.